Recombinant Human Erythropoietin Treatment in Pre-Dialysis Patients

Publisher Website
Google Scholar
Abstract
Study Objective: To determine the efficacy and safety of recombinant human erythropoietin (r-HuEPO) in predialysis renal patients. Design: Randomized, double-blind, placebo-controlled trial for 8 weeks. Setting: Inpatient and outpatient facility in the Clinical Research Center of a university-based hospital. Patients: Fourteen adult subjects with renal insufficiency (mean serum creatinine, 473 .mu.mol/L .+-. 61 [6.2 .+-. 0.8 mg/ dL]) and anemia (mean hematocrit, 0.27 .+-. 0.01). Interventions: Recombinant human erythropoietin, 50, 100, or 150 IU/kg body weight or placebo given intravenously three times per week. Measurements and Main Results: Subjects who received active r-HuEPO showed a dose-dependent rise in hematocrit; mean hematocrit increased 41% from 0.27 .+-. 0.01 to 0.38 .+-. 0.01. At the same time, erythrocyte mass rose 43% from 13.7 .+-. 0.6 mL/kg in the baseline state to 19.6 .+-. 1.0 mL/kg after treatment. Maximal oxygen consumption during exercise increased 9% from 16.0 mL/min .cntdot. kg .+-. 1.8 to 17.5 mL/min .cntdot. kg .+-. 1.9. Conclusions: Recombinant human erythropoietin is effective and safe in ameliorating the anemia of pre-dialysis patients.